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b-thalassemia is a hereditary disorder with limited approved treatment options; patients
experience anemia and its complications, including iron overload. The study aim was to
determine whether luspatercept could improve anemia and disease complications in
patients with b-thalassemia. This open-label, nonrandomized, uncontrolled study consisted
of a 24-week dose-finding and expansion stage (initial stage) and a 5-year extension stage,
currently ongoing. Sixty-four patients were enrolled; 33 were non–transfusion dependent
(mean hemoglobin, <10.0 g/dL; <4 red blood cell [RBC] units transfused per 8 weeks), and
31 were transfusion dependent (‡4 RBC units per 8 weeks). Patients received 0.2 to
1.25 mg/kg luspatercept subcutaneously every 21 days for ‡5 cycles (dose-finding stage)
and 0.8 to 1.25 mg/kg (expansion cohort and 5-year extension). The primary end point was
erythroid response, defined as hemoglobin increase of ‡1.5 g/dL from baseline for ‡14
consecutive days (without RBC transfusions) for non–transfusion-dependent patients or
RBC transfusion burden reduction ‡20% over a 12-week period vs the 12 weeks before
treatment for transfusion-dependent patients. Eighteen non–transfusion-dependent
patients (58%) receiving higher dose levels of luspatercept (0.6-1.25 mg/kg) achieved
mean hemoglobin increase ‡1.5 g/dL over ‡14 days vs baseline. Twenty-six (81%) transfusion-dependent patients
achieved ‡20% reduction in RBC transfusion burden. The most common grade 1 to 2 adverse events were bone
pain, headache, and myalgia. As of the cutoff, 33 patients remain on study. In this study, a high percentage of
b-thalassemia patients receiving luspatercept had hemoglobin or transfusion burden improvements. These findings
support a randomized clinical trial to assess efficacy and safety. This studywas registered at www.clinicaltrials.gov as
#NCT01749540 and #NCT02268409. (Blood. 2019;133(12):1279-1289)
Introduction
b-thalassemia is a hereditary red blood cell (RBC) disorder
caused by mutations in the b-globin gene.1 These mutations
lead to oxidative stress and premature death of erythroblasts,
resulting in ineffective erythropoiesis and erythroid expansion in
the bone marrow.2,3 Comorbidities, including bone deformities,
splenomegaly, and leg ulcers, are the result of 1 or more factors
associated with the disease, including ineffective erythropoiesis,
anemia, and iron overload.1
Patients with b-thalassemia major have a severe form of the
disease and are generally transfusion dependent. However,
receiving regular RBC transfusions leads to iron overload, ne-
cessitating daily iron chelation therapy.4 b-thalassemia inter-
media includes less severe forms of the disease that may be
initially non–transfusion dependent but over time may become
transfusion dependent. Although these patients are generally
non–transfusion dependent, iron overload can result from in-
creased intestinal iron absorption because of reduced hepcidin
levels.5 Sporadic or even regular transfusions may therefore be
required.4,6,7
Current treatment options forb-thalassemia aremostly limited to
supportive therapy. Hematopoietic stem cell transplantation is
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currently the only possible curative treatment; however, it is
only suitable for a small percentage of patients.8 Gene therapy
clinical trials for b-thalassemia are in the early stages.9 The use
of erythropoiesis-stimulating agents, such as erythropoietin, in
b-thalassemia is not supported by controlled clinical trials.10,11
Members of the transforming growth factor b superfamily of
ligands, including growth differentiation factors and activins,
have been shown to act as inhibitors of late-stage erythropoi-
esis.12 Luspatercept (ACE-536) is a novel recombinant fusion
protein that acts as a trap for these ligands. In healthy volunteers,
luspatercept was well tolerated and associated with dose-
dependent increases in hemoglobin levels.13 RAP-536, a murine
analog of luspatercept, has also been shown to reduce oxida-
tive stress and anemia in a mouse model of b-thalassemia.14
The aim of this phase 2 study was to determine a tolerable and




The study was approved by the institutional review board or
central ethics committee at each participating institution and
was conducted in accordance with the Declaration of Helsinki.
All patients provided written informed consent. Patients were
enrolled between 11 February 2013 and 6 July 2015 at 8 sites
in Italy and Greece. Detailed information on the sites where
patients were recruited is provided in supplemental Table 1
(available on the Blood Web site).
Patients
Patients with a documented diagnosis of b-thalassemia age
$18 years were eligible. Those in the dose-escalation stage had
either prior splenectomy or spleen size ,18 cm at the longest
diameter, as measured by abdominal ultrasound.
Exclusion criteria included folate deficiency, symptomatic
splenomegaly, and history of thromboembolic events; individuals
with adequate folate replacement therapy could be enrolled.
Patients with any clinically significant pulmonary, cardiovascular,
endocrine, neurologic, hepatic, gastrointestinal, infectious, im-
munologic, or genitourinary disease considered by the investi-
gator to be inadequately controlled were also excluded.
Eligible patients were classified as either non–transfusion de-
pendent or transfusion dependent. Patients not dependent on
transfusions were eligible if they had a mean hemoglobin
concentration of ,10.0 g/dL (based on $2 measurements) and,
if transfused, received,4 RBC units in the 8 weeks before study
initiation. Patients with transfusion dependence were those who
received an average of $4 RBC units every 8 weeks over the
6-month period before study initiation.
Study design
This phase 2, open-label, nonrandomized, uncontrolled, dose-
finding study evaluated the effects of luspatercept in patients
with b-thalassemia. Luspatercept was administered subcu-
taneously every 21 days at dose levels ranging from 0.2 to
1.25 mg/kg of body weight; this starting dose was selected
based on preclinical and phase 1 clinical findings, including
safety margin and pharmacodynamic markers.
The study was conducted in 2 stages: the initial stage and ex-
tension stage (Figure 1). In the dose-escalation cohorts of the
initial stage, patients received up to 5 doses of luspatercept at
1 of 6 prespecified dose levels: 0.2, 0.4, 0.6, 0.8, 1.0, and
1.25 mg/kg. There was no formal sample size calculation used in
the dose-finding stage. Up to 6 individuals were enrolled in each
dose level, and dose cohorts were enrolled sequentially, from
lowest to highest dose group. Once$3 patients in a dose cohort
completed the study day-29 visit, response and AE data were
reviewed by a safety review team comprising the coordinating
investigator, medical monitor, and an independent hematolo-
gist. The safety review team made recommendations as to
whether to enroll patients in the next highest dose cohort or
proceed to the expansion cohort at a selected dose level.
After the dose-escalation cohorts, an expansion cohort was
enrolled. On the basis of recommendations of the safety review
team, individuals in the expansion cohort received luspatercept
at a starting dose level of 0.8 mg/kg, with dose titration up
to 1.25 mg/kg allowed after completion of 2 treatment cycles.
A sample of 30 evaluable patients in the expansion cohort was
calculated by a priori power analysis to provide ;87% power
(with a 1-sided significance level of .05) to differentiate an
erythroid response rate of 30% from a minimal erythroid re-
sponse rate of 10%. Patients were on study for;24 weeks in the
initial stage, including a 4-week screening period, 12-week treat-
ment period, and 8-week follow-up period.
Patients completing the initial stage could be enrolled in the
long-term extension stage to receive luspatercept for up to
5 years. Those without treatment interruption could directly roll
over to the extension stage at a starting dose equal to their last
dose level in the initial stage. Those with treatment interrup-
tion were reassessed for eligibility and transfusion status before
starting the extension and received a starting dose level of
0.8 mg/kg. In this manner, patients classified as non–transfusion
dependent in the base study could be reclassified as transfusion
dependent upon entering the extension study, or vice versa,
subject to transfusion status evaluation. Dose titration up to
1.25 mg/kg was allowed in the extension stage. Patients dis-
continuing or completing the extension stage entered a 2-month
follow-up period. Additional study design and statistical in-
formation can be found in the supplemental Methods.
Study end points
Primary end point The primary end point was erythroid re-
sponse, defined as a hemoglobin increase from baseline of
$1.5 g/dL for $2 weeks (in the absence of RBC transfusions) for
non–transfusion-dependent patients and as a reduction in RBC
transfusion burden over a 12-week interval of $20% as com-
pared with pretreatment for transfusion-dependent patients.
Secondary end points Secondary end points reported in this
manuscript include hemoglobin increase of $1.5 g/dL from
baseline for $12 consecutive weeks for non–transfusion-
dependent patients, reduction in RBC transfusion burden of
$33% or$50% for transfusion-dependent patients, time to and
duration of erythroid response, and changes in liver iron con-
centration (LIC) measured using magnetic resonance imaging.
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The time to response was calculated from the day patients re-
ceived the first dose to the beginning of the first 12-week rolling
period in which they satisfied the response criterion.
The safety and tolerability of luspatercept was evaluated through-
out the study, including AE profiling, clinical laboratory tests, and
vital signs. Additional secondary end point assessments beyond
the scope of this manuscript include the proportion of patients
requiring no RBC transfusions for $8 consecutive weeks, addi-
tional iron metabolism parameters, erythropoiesis parameters,
bone metabolism parameters, and hemolysis parameters.
Exploratory end points Exploratory end points included
quality of life, which was measured using the Functional As-
sessment of Chronic Illness Therapy–Fatigue (FACIT-F) patient-
reported outcome tool. The FACIT-F scale ranges from 0 to 52,
with 52 being the best quality of life.15 Other secondary end
points reported included improvements in leg ulcers and bone
mineral density (BMD) by dual-energy X-ray absorptiometry
scan. Leg ulcer severity was scored using a scale of 0 to 5, where
0 denoted fully healed and 5 denoted gangrene, as well as with
measurements; however, some leg ulcers were only graded by
physical examination and measurements.16 Information on when
and how the end points in this study were collected, including
those not reported in this manuscript, can be found in sup-
plemental Table 2.
Statistical methods
The primary efficacy end point of erythroid response is sum-
marized by percentage of responders and its 95% exact con-
fidence interval (CI). For secondary and exploratory efficacy
end points, the continuous measurement data, including LIC,
hemoglobin, duration of erythroid response, and BMD, are sum-
marized by mean change from baseline and corresponding
Assessed for eligibility (N = 75) 
Enrolled in initial stage (N = 64) 
   • Assigned to the dose-escalation cohorts*
      (n = 35)
    • 23 NTD and 12 TD patients
   • Assigned to the expansion cohort† (n = 29)
Still on extension (N = 33) 
Follow-up§
Entered extension stage† (N = 51)
   • Direct rollover to extension stage (n = 26)
    • 10 NTD and 16 TD patients
   • Interrupted entry‡ to extension stage (n = 25)
    • 17 NTD and 8 TD patients  
Completed  initial stage (N = 61)
Excluded (N = 11)
   • Not meeting inclusion criteria (n =  11) 
Discontinued extension stage (N = 18)
   • Medical reason or AE (n = 4)
   • Lost to follow-up (n  = 1) 
   • Patient request (n = 10)
   • Death (n = 1)
   • Protocol non-compliance (n = 2)    
Discontinued from initial stage (N = 3)
   • Patient request (n = 1)
   • Protocol non-compliance (n = 2)
Did not enter extension stage (N = 10)









Figure 1. Study design and cohorts. The analytic sample size for the primary study end point was 63 patients (non–transfusion dependent [NTD], n5 31; transfusion dependent
[TD], n5 32); this included all patients who received 0.6 to 1.25 mg/kg of luspatercept in either the initial or extension stage of the study. Doses,0.6 mg/kg of luspatercept were
not considered efficacious. *Patients assigned to the dose-escalation cohorts received luspatercept at dose levels of 0.2 to 1.25 mg/kg; patients were assigned to the following
dose levels: 0.2 mg/kg (n5 6 patients; all NTD), 0.4 mg/kg (n5 6 patients; all NTD), 0.6 mg/kg (n5 5 NTD patients; n5 1 TD patient), 0.8 mg/kg (n5 3 NTD patients; n5 3 TD
patients), 1.0 mg/kg (n 5 2 NTD patients; n 5 4 TD patients), and 1.25 mg/kg (n 5 1 NTD patient; n 5 4 TD patients). †Patients assigned to the expansion cohort and the
extension stage received luspatercept at dose levels of 0.8 to 1.25 mg/kg; patients were assigned to the expansion cohort after review of adverse event (AE) and efficacy data for
patients in the dose-escalation cohorts. ‡Patients entering the extension with treatment interruption were those who had finished the initial stage of treatment and had
completed the end-of-study visit at least 28 days before receiving the first dose in the extension. §Patients enter the 2-month follow-up after discontinuing from or completing
the extension stage; because of the treatment period of 60 months, no patients have yet entered the follow-up period.
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standard deviation (SD) and 95% CI, as required. The dichoto-
mized response measurement data, including $33% and
$50% RBC transfusion reduction from baseline, are summarized
by percentage of response and 95% CI. Correlation between
improvement in FACIT-F and hemoglobin change is summarized
using the Pearson correlation coefficient and tested to de-
termine the significance of this correlation. P values presented
are based on a 2-sided test; P values ,.05 were considered
statistically significant. SAS statistical software was used (version
9.4; SAS Institute, Cary, NC). Changes from baseline hemo-
globin values were further evaluated by mixed-effects analysis
with baseline hemoglobin, investigational sites, and time; of these,
sites and time were treated as random effects.
With regard to missing values when calculating the primary end
point, a patient without adequate data for evaluation was con-
sidered a nonresponder. For example, any patient without
12-week RBC transfusion data after treatment was considered
a nonresponder for the purpose of calculating erythroid re-
sponse. For other patient data, including LIC, BMD, and quality




Sixty-four patients were enrolled between 11 February 2013 and
6 July 2015. In the initial stage, patients received luspatercept
every 3 weeks for up to 5 doses (median exposure, 105 days;
range, 21-107 days). Thirty-five of the 64 patients were enrolled
in the dose-escalation cohorts (0.2-1.25 mg/kg), and 29 were
enrolled in the expansion cohort (0.8-1.25 mg/kg). At baseline,
33 patients were non–transfusion dependent and 31 were
transfusion dependent.
In the initial stage of the study, 12 patients received luspatercept at
lower dose levels of 0.2 to 0.4 mg/kg and 52 patients at higher dose
levels of 0.6 to 1.25 mg/kg; all 12 lower-dose patients were non–
transfusion dependent. A total of 51 patients carried over to the
long-term extension stage of the study, during which all patients
received higher dose levels of 0.6 to 1.25 mg/kg; 25 of these
patients had treatment interruption between treatment stages.
Median total duration of treatment of all 64 patients was
428 days (range, 21-768 days); treatment of 33 patients was
ongoing as of the 2 September 2016 data cutoff date. Of the
18 patients who discontinued the extension stage, 4 did so
because of a medical reason or AE, 1 was lost to follow-up, 10
discontinued at patient request, 1 died as a result of a cerebro-
vascular accident not related to treatment, and 2 discontinued
because of protocol noncompliance (Figure 1).
Of the 51 patients who continued to the extension stage, 11 had
received lower dose levels in the initial stage. Thus, across both
stages of the study, 63 of 64 patients received higher dose levels
of 0.6 to 1.25 mg/kg of luspatercept at some point during
the study; 31 were non–transfusion dependent, and 32 were
transfusion dependent.
Table 1. Patient demographics and baseline characteristics
Initial luspatercept dose groups, mg/kg
Total (N 5 64)0.2-0.4 (n 5 12) 0.6-1.25 (n 5 52)
Age, median (range), y 33.5 (22-53) 41.0 (20-62) 38.5 (20-62)
Female, n (%) 5 (42) 26 (50) 31 (48)
Splenectomy, n (%) 10 (83) 33 (64) 43 (67)
Non–transfusion-dependent patients, n 12 21 33
Hemoglobin, median (range), g/dL 8.5 (7.0-9.6) 8.5 (6.5-9.8) 8.5 (6.5-9.8)
LIC, mean (SD), mg/g dry weight 5.1 (2.9) 5.6 (4.3) 5.4 (3.8)
Transfusion-dependent patients, n 0 31 31
RBC transfusion burden, median (range), units/12 wk* NA 8.0 (4-18) 8.0 (4-18)
LIC, mean (SD), mg/g dry weight† NA 5.0 (5.3) 5.0 (5.3)
BMD
Total hip, mean (SD), z score 21.1 (0.90) 20.66 (1.27) 20.74 (1.21)
Lumbar spine, mean (SD), z score 21.62 (0.58) 21.61 (0.95) 21.61 (0.88)
FACIT-F score, median (range)‡ NA 41.5 (25-48) 41.5 (25-48)
NA, not applicable; SD, standard deviation.
*Baseline RBC transfusion burden is defined as the total number of RBC units transfused in the 12 wk before first dose of luspatercept (and confirmed over 6 mo before treatment).
†LIC data were not available at baseline for 1 of the 31 transfusion-dependent patients.
‡FACIT-F score was assessed in 26 of the 64 patients, none of whom received 0.2-0.4 mg/kg of luspatercept. For scoring assessment, a scale of 0 to 52 is used, with 0 indicating worst
quality of life and 52, best. A score ,44 points is considered to be a FACIT-F deficit.16
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Patient demographics and baseline characteristics are listed in
Table 1.16 Median age at baseline was 38.5 years (range, 20-62
years), and 48% of patients were women. Among patients who
were non–transfusion dependent, median hemoglobin level at
baseline was 8.5 g/dL (range, 6.5-9.8 g/dL), whereas mean (6 SD)
LIC was 5.4 6 3.8 mg/g dry weight. Among patients with
transfusion dependence, median baseline transfusion burden
was 8.0 RBC units per 12 weeks (range, 4-18 units), andmean LIC
was 5.0 6 5.3 mg/g. In total, 43 patients (67%) had previously
had a splenectomy.
Efficacy
Hemoglobin response in non–transfusion-dependent patients
Primary end point Rates of erythroid response for non–transfusion-
dependent patients are listed in Table 2. Of 31 non–transfusion-
dependent patients treatedwith luspatercept at dose levels of 0.6
to 1.25 mg/kg, 18 (58%) achieved a mean hemoglobin increase
from baseline of $1.5 g/dL over 14 consecutive days (95% CI,
39.1-75.5).
Secondary end points Of 31 non–transfusion-dependent patients
treated with luspatercept at dose levels of 0.6 to 1.25 mg/kg,
22 (71%) achieved a mean hemoglobin increase from baseline
of $1.0 g/dL over 12 weeks (95% CI, 52.0-85.8) compared with the
12 weeks before treatment; 14 (45%) non–transfusion-dependent
patients achieved a mean hemoglobin increase of $1.5 g/dL over
12 weeks (95% CI, 27.3-64.0). Of 10 non–transfusion-dependent
patients with prior splenectomy receiving luspatercept at dose
levels of 0.6 to 1.25 mg/kg, 8 (80%) achieved a mean hemoglobin
increase from baseline of$1.5 g/dL over 12 weeks, compared with
6 (29%) of 21 patients without prior splenectomy. The relationship
between splenectomy and response will be investigated further in
a future trial.
Mean hemoglobin changes from baseline for those treated with
luspatercept at dose levels of 0.2 to 0.4 mg/kg and 0.6 to
1.25mg/kg in the initial stage of the study are shown in Figure 2A.
Median time to hemoglobin response among non–transfusion-
dependent patients in the initial stage of the study was 8 days
(range, 7-30 days). Mean change in hemoglobin over the study
duration, including the extension stage up to 18 months total
duration, for all non–transfusion-dependent patients treated
with dose levels of 0.6 to 1.25 mg/kg (n 5 31) is shown in
Figure 2B.
Transfusion burden reduction in transfused patients
Primary end point Thirty-two patients with transfusion de-
pendence were treated with luspatercept at dose levels of 0.6 to
1.25 mg/kg during the study. Of these, 26 (81%) achieved
a transfusion burden reduction of $20% over any 12 weeks on
study compared with the 12 weeks before baseline (95% CI,
63.6-92.8); these data are presented in Table 2.
Secondary end points RBC transfusion burden reduction of
$33%was achieved in 23 patients (72%; 95% CI, 53.3-86.3), and
$50% reduction was achieved in 20 (63%; 95% CI, 43.7-78.9).
Of 21 transfusion-dependent patients with prior splenectomy,
14 (67%) achieved a transfusion burden reduction of$20% over
a fixed 12-week period vs baseline, compared with 4 (36%) of
11 patients without prior splenectomy.
Transfusion burden reduction relative to pretreatment of all trans-
fused patients who had a baseline transfusion burden of $2 RBC
units and received 0.6 to 1.25 mg/kg of luspatercept is shown in
Figure 3. For transfused patients, mean transfusion burden (6 SD)
over the best recorded 12-week responses on treatment was 3.0
units (63.76), compared with 7.6 units (63.56) at baseline. The pre-
transfusion hemoglobin levels did not vary substantially on treatment
as compared with pretreatment and ranged between 9 and 10 g/dL.
LIC
Secondary end point Of 15 patients with non–transfusion-
dependent b-thalassemia with baseline LIC $3 mg/g dry
weight who were treated for $4 months, 5 (33%) achieved
a decrease in LIC $2 mg/g dry weight (95% CI, 11.8-61.6;
Figure 4A). Mean LIC (6 SD) for non–transfusion-dependent
Table 2. Response rates based on erythroid response criteria in patients with b-thalassemia
0.6-1.25 mg/kg luspatercept (N 5 63)* 95% CI
Non–transfusion-dependent patients, n/N (%) n 5 31†
Mean hemoglobin increase, g/dL
$1.5 for 14 d‡ 18/31 (58) 39.1-75.5
$1.0 for 12 wk 22/31 (71) 52.0-85.8
$1.5 for 12 wk 14/31 (45) 27.3-64.0
Decrease in LIC $2 mg/g dry weight§ 5/15 (33) 11.8-61.6
Transfusion-dependent patients, n/N (%) n 5 32†
Transfusion burden reduction, %
$20‡ 26/32 (81) 63.6-92.8
$33 23/32 (72) 53.3-86.3
$50 20/32 (63) 43.7-78.9
Decrease in LIC $2 mg/g dry weight§ 5/9 (56) 21.2-86.3
Results shown are the numbers of patients achieving any of the specified end points over any unbroken 12-wk period on study compared with baseline; only patients receiving dose levels
of 0.6-1.25 mg/kg of luspatercept at any time during the study are shown (63 of 64 total patients; initial and extension stages).
*One of the 64 patients initially enrolled is not included because the patient did not receive luspatercept $0.6 mg/kg during the study.
†One patient classified as non–transfusion dependent during the initial stage of the study was reclassified as transfusion dependent before entering the extension stage and is counted
as transfusion dependent in the table.
‡Primary end point; other end points shown are secondary end points.
§Includes patients with baseline LIC $3 mg/g dry weight who were treated for $4 mo.
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patients at the end of the initial stage of treatment was 20.36
mg/g dry weight (61.59), compared with 5.38 mg/g (63.79) at
baseline. Of 9 patients with transfusion dependence with base-
line LIC $3 mg/g dry weight who were treated for $4 months,
5 (56%) achieved a decrease in LIC $2 mg/g dry weight
(95% CI, 21.2-86.3; Figure 4B). Mean LIC (6 SD) for transfusion-
dependent patients at the end of the initial stage of treatment
was 20.27 mg/g dry weight (61.64), compared with 5.03 mg/g
(65.32) at baseline. All LIC responders were receiving ongoing
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Figure 2. Mean (6 95% CI) change in hemoglobin level relative to baseline. (A) Non–transfusion-dependent patients with b-thalassemia treated with luspatercept at
0.2 to 0.4 mg/kg compared with 0.6 to 1.25 mg/kg during the initial stage of the study. (B) All non–transfusion-dependent patients with b-thalassemia treated with luspatercept
at 0.6 to 1.25 mg/kg during the initial and/or extension stage of the study.
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Figure 3. Transfusion burden reduction vs baseline for patients with b-thalassemia treated with luspatercept (n5 32). (A) Percentage change in RBC transfusion burden
over a continuous 12-week period post baseline vs the 12-week baseline period. Each bar represents 1 patient; the best recorded continuous 12-week period of transfusion
burden reduction post baseline was used to calculate the percentage change for each patient. (B) Absolute change in RBC units on study vs baseline. Each circle represents
1 patient’s baseline RBC transfusion burden, as absolute number of transfused units in a 12-week period; each line represents the best recorded transfusion burden reduction for
the patient over a continuous 12-week period post baseline. For both panels, only patients with a baseline transfusion burden of $2 RBC units and 12-week postbaseline
transfusion data are shown.
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Exploratory end points
Leg ulcers Six patients had from1 to6 legulcers over themalleoli at
baseline. Each of the 6 patients had complete healing of at least 1
ulcer, with a total of 9 ulcers fully healed, 2 partially healed, and3not
improved. Median time to complete healing was 10 weeks (range,
6-33 weeks). An example of ulcer healing is illustrated in Figure 5.
BMD Those receiving luspatercept were assessed for changes
in BMD. On baseline dual-energy X-ray absorptiometry scans,
mean (6 SD) BMD z score was20.746 1.21 for total hip (n5 25)
and 21.61 6 0.88 for lumbar spine (n 5 27). After 24 weeks
of treatment at dose levels $0.6 mg/kg, mean percentage
change in BMD was 15.3% 6 15.8% for total hip (n 5 14;
P 5 .23) and 13.1% 6 6.6% for lumbar spine (n 5 17; P 5 .07).
Quality of life Quality-of-life changes were measured using
the FACIT-F patient-reported outcome tool.15 Improvements in
FACIT-F score in non–transfusion-dependent patients were
significantly correlated with mean 12-week change in hemo-
globin (n 5 21; r 5 0.64; P 5 .002). Of the non–transfusion-
dependent patients with a baseline FACIT-F deficit (,44 points)
compared with normative data,17 7 (78%) of 9 improved by $3
points at 24 weeks. A majority of these patients (86%) also had
an improvement in mean hemoglobin of$1.0 g/dL over a 12-week
period. As expected, we did not observe any significant
changes in transfusion-dependent patients.
AEs AEs assessed as treatment related are listed in Table 3.
Grade 1 to 2 AEs were common, mainly during the first 8 weeks,
0
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Figure 4. LIC change in non–transfusion-dependent (A)
and transfusion-dependent b-thalassemia patients (B).
Each filled circle represents 1 patient’s baseline LIC; each
line represents the best recorded change in LIC post
baseline. Only patients with $4 months postbaseline LIC
are included. Patients noted to have received iron chelation
therapy could have received it in the 84 days before treat-
ment as well as on study. dw, dry weight.
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with a clear trend to decrease. The most frequent were bone
pain, headache, myalgia, arthralgia, musculoskeletal pain, back
pain, and injection site pain. Grade 3 AEs considered treatment
related were uncommon, with 6 reported in 5 patients (8%): 3
reports of grade 3 bone pain, 2 of grade 3 asthenia, and 1 of
grade 3 headache. No treatment-related grade 4 AEs or serious
AEs were reported. One patient with a history of cardiac disease
died as a result of cardiac arrest considered unrelated to treat-
ment; no treatment-related deaths were reported. Four (6%) of
64 patients discontinued treatment because of AEs. AEs were
more frequent during the first 8 weeks, with a trend to decrease
over time. Dose-delay and full AE information can be found in the
supplemental Results and supplemental Table 3, respectively.
Results pertaining to luspatercept pharmacokinetics are located in
the supplemental Results as well.
Discussion
In this phase 2 study of patients with b-thalassemia, the primary
finding was the achievement of protocol-defined erythroid re-
sponse, which occurred in 71% of non–transfusion-dependent
patients and 81% of transfusion-dependent patients receiving
higher doses of luspatercept. Population pharmacokinetic mod-
eling suggests that luspatercept at 1.0 mg/kg is an appropriate
starting dose for additional studies in patients with b-thalassemia,
with titration up to 1.25 mg/kg if required to achieve optimal
exposure.18
Luspatercept is a novel recombinant fusion protein containing
a modified activin receptor type IIB (ActRIIB, ACVR2B) that acts
as a ligand trap to block inhibitors of late-stage erythropoiesis.12
In this manner, luspatercept functions as an erythroid maturation
agent to restore RBC production and ameliorate anemia. To
date, most AEs reported in patients with b-thalassemia receiving
luspatercept have been grade 1 or 2; few patients reported grade
3 to 4 AEs. In this study, the most frequent treatment-related
AE, bone pain, was more commonly observed in patients with
transfusion dependence and may have been due in part to the
withdrawal of transfusions in response to treatment. Collection
of longer-term AE data is ongoing in the extension stage of
the study.
In this study, most patients with low FACIT-F quality-of-life fa-
tigue scores at baseline had improved scores after luspatercept
treatment. Most patients with low baseline fatigue scores who
achieved an erythroid response had improvements in FACIT-F
score during the study. Although the FACIT-F questionnaire
focuses on the symptoms of anemia, transfusion-dependent
patients were also assessed, and no significant change in score
was observed posttreatment. This could be expected for patients
who were asymptomatic at baseline with hemoglobin levels
maintained during treatment.
Iron overload affects patients with b-thalassemia regardless of
whether they are transfusion dependent or non–transfusion de-
pendent. In non–transfusion-dependent b-thalassemia patients,
abnormal regulation of intestinal absorption leads to iron over-
load, whereas in patients with transfusion dependence, iron
overload occurs mostly as a result of frequent RBC transfusions.3,5
Despite the availability of iron chelation therapies, mean
baseline LIC determined by magnetic resonance imaging was
found to be abnormal in both non–transfusion-dependent and
transfusion-dependent patients, with a mean concentration of
5.4 and 5.0 mg/g dry weight, respectively. Luspatercept treat-
ment was associated with clinically significant decreases in LIC,
particularly in patients who had baseline LIC$3 mg/g dry weight
and who were receiving concomitant iron chelation therapy;
the relative contributions of luspatercept and iron chelation ther-
apy cannot be resolved.
Erythroid expansion resulting from ineffective erythropoiesis in
b-thalassemia can lead to skeletal deformities and decreased
BMD,19 which improved with luspatercept treatment in mouse
models of the disease.14 Patients in this study had low mean
baseline total hip and lumbar spine BMD z scores, with increases
during treatment with luspatercept that were not found to be
statistically significant.
Pre-Treatment After 6 Weeks
Figure 5. Leg ulcer healing in a patientwith non–transfusion-
dependent b-thalassemia treated with luspatercept. The
patient received 0.4 mg/kg of luspatercept in the initial stage of
the study and up to 1.25 mg/kg of luspatercept in the extension
stage. The image example shown is representative of an ulcer
that healed within 6 weeks.
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Severe anemia, ineffective erythropoiesis, iron overload, and
hypercoagulable state are potential risk factors for developing
leg ulcers in b-thalassemia, particularly in nontransfused patients.20
Of the 6 patients with leg ulcers, which were often long-standing
and resistant to other therapies, all had complete healing of
1 or more leg ulcers, which may have been due to drug effects on
anemia, ineffective erythropoiesis, and/or iron overload, as well as
transforming growth factor b superfamily signaling pathways; the
mechanism is the subject of further ongoing research.
The study has several limitations. First, it had a single-group,
open-label design without a control group for comparison. How-
ever, the lower-dose groups were considered subtherapeutic.
Second, the study had a relatively small number of patients
treated at different dose levels. Higher-dose groups with
similar responses were pooled for this reason. Third, many
patients had normal baseline BMD; the small numbers of
patients with low BMD limited the analysis and interpretation of
the effects of luspatercept. Fourth, the notable decreases in LIC
were confounded by patients receiving concomitant chronic
treatment with iron chelation therapy. Nonetheless, decreases
in LIC may have been due in part to the decrease of transfusion
burden and/or increase in iron utilization related to luspatercept
treatment.
In conclusion, in this open-label, nonrandomized, uncontrolled
dose-finding study of patients with b-thalassemia, a high per-
centage had improvement in hemoglobin or transfusion burden
after use of luspatercept. These findings support a randomized
clinical trial to assess efficacy and safety.
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Table 3. AEs considered related to treatment occurring
during the study (N 5 64)
AE preferred term*
Related TEAE, n (%)
Grade 1-2 in
‡2 patients Grade 3†
Bone pain 21 (33) 3 (5)
Headache 16 (25) 1 (2)
Myalgia 13 (20) 0
Arthralgia 12 (19) 0
Musculoskeletal pain 10 (16) 0
Back pain 7 (11) 0
Injection site pain 7 (11) 0
Asthenia 6 (9) 2 (3)
Erythroblastosis 3 (5) 0
Injection site erythema 3 (5) 0
Musculoskeletal chest pain 3 (5) 0
Neck pain 3 (5) 0
Pain in jaw 3 (5) 0
Pyrexia 3 (5) 0
Chills 2 (3) 0
Influenza 2 (3) 0
Injection site pruritus 2 (3) 0
Macules 2 (3) 0
Muscle spasms 2 (3) 0
Nausea 2 (3) 0
Pain in extremity 2 (3) 0
Paresthesia 2 (3) 0
Maximum severity reported per patient per preferred term.
TEAE, treatment-emergent AE.
*Classified according to the Medical Dictionary for Regulatory Activities. Results shown are
the numbers of patients reporting the specified TEAEs.
†No grade 4 AEs considered related to luspatercept treatment were reported.




 http://ashpublications.org/blood/article-pdf/133/12/1279/1552861/blood879247.pdf by guest on 08 April 2021
ORCID profile: I.T., 0000-0003-1278-2372.
Correspondence: Antonio Piga, Department of Clinical and Biological
Sciences, Turin University, Regione Gonzole, 10, 10043 Orbassano, Turin,
Italy; e-mail: antonio.piga@unito.it.
Footnotes
Submitted 9 October 2018; accepted 18 December 2018. Prepublished
online as Blood First Edition paper, 7 January 2019; DOI 10.1182/blood-
2018-10-879247.
Data requests may be submitted to Celgene at www.celgeneclini-
caldatasharing.com and must include a description of the research
proposal.
The online version of this article contains a data supplement.
There is a Blood Commentary on this article in this issue.
The publication costs of this article were defrayed in part by page
charge payment. Therefore, and solely to indicate this fact, this article is
hereby marked “advertisement” in accordance with 18 USC section
1734.
REFERENCES
1. Galanello R, Origa R. Beta-thalassemia.
Orphanet J Rare Dis. 2010;5:11.
2. Rund D, Rachmilewitz E. Beta-thalassemia.
N Engl J Med. 2005;353(11):1135-1146.
3. Melchiori L, Gardenghi S, Rivella S.
b-thalassemia: HiJAKing ineffective erythro-
poiesis and iron overload.Adv Hematol. 2010;
2010:938640.
4. Rachmilewitz EA, Giardina PJ. How I treat
thalassemia. Blood. 2011;118(13):3479-3488.
5. Origa R, Galanello R, Ganz T, et al. Liver iron
concentrations and urinary hepcidin in beta-
thalassemia. Haematologica. 2007;92(5):
583-588.
6. Saliba AN, Taher AT. Morbidities in non-
transfusion-dependent thalassemia. Ann N Y
Acad Sci. 2016;1368(1):82-94.
7. Taher AT, Musallam KM, Karimi M, Cappellini
MD. Contemporary approaches to treatment
of beta-thalassemia intermedia. Blood Rev.
2012;26(suppl 1):S24-S27.
8. Angelucci E, Matthes-Martin S, Baronciani D,
et al; EBMT Inborn Error and EBMT Paediatric
Working Parties. Hematopoietic stem cell
transplantation in thalassemia major and sickle
cell disease: indications and management
recommendations from an international
expert panel. Haematologica. 2014;99(5):
811-820.
9. Thompson AA, Walters MC, Kwiatkowski J,
et al. Gene therapy in patients with
transfusion-dependent b-thalassemia. N Engl
J Med. 2018;378(16):1479-1493.
10. Gardenghi S, Grady RW, Rivella S. Anemia,
ineffective erythropoiesis, and hepcidin:
interacting factors in abnormal iron metabo-
lism leading to iron overload in b-thalassemia.
Hematol Oncol Clin North Am. 2010;24(6):
1089-1107.
11. Fibach E, Rachmilewitz EA. Does erythropoi-
etin have a role in the treatment of
b-hemoglobinopathies? Hematol Oncol
Clin North Am. 2014;28(2):249-263.
12. Suragani RN, Cawley SM, Li R, et al. Modified
activin receptor IIB ligand trap mitigates in-
effective erythropoiesis and disease compli-
cations in murine b-thalassemia. Blood. 2014;
123(25):3864-3872.
13. Attie KM, AllisonMJ,McClure T, et al. A phase
1 study of ACE-536, a regulator of erythroid
differentiation, in healthy volunteers. Am
J Hematol. 2014;89(7):766-770.
14. Martinez PA, Suragani RN, Bhasin M, Li R,
Pearsall RS, Kumar R. RAP-536 (murine ACE-
536/luspatercept) inhibits Smad2/3 signaling
and promotes erythroid differentiation by
restoring GATA-1 function in murine
b-thalassemia [abstract]. Blood. 2015;126(23).
Abstract 751.
15. Functional Assessment of Chronic Illness
Therapy (FACIT). Questionnaires. http://www.
facit.org/facitorg/questionnaires. Accessed
16 January 2018.
16. Minniti CP, Eckman J, Sebastiani P, Steinberg
MH, Ballas SK. Leg ulcers in sickle cell disease.
Am J Hematol. 2010;85(10):831-833.
17. Cella D, Lai JS, Chang CH, Peterman A, Slavin
M. Fatigue in cancer patients compared with
fatigue in the general United States pop-
ulation. Cancer. 2002;94(2):528-538.
18. Chen N, Laadem A, Wilson DM, et al.
Pharmacokinetics and exposure-response of
luspatercept in patients with beta-thalasse-
mia: preliminary results from phase 2 studies
[abstract]. Blood. 2016;128(22). Abstract
2463.
19. Nienhuis AW, Nathan DG. Pathophysiology
and clinical manifestations of the
b-thalassemias. Cold Spring Harb Perspect
Med. 2012;2(12):a011726.
20. Leg ulcers. In: Taher A, Vichinsky E, Musallam
K, Cappellini MD, Viprakasit V, Weatherall D,
eds. Guidelines for the Management of Non
Transfusion Dependent Thalassaemia (NTDT).
Nicosia, Cyprus: Thalassaemia International
Federation; 2013:94-97.




 http://ashpublications.org/blood/article-pdf/133/12/1279/1552861/blood879247.pdf by guest on 08 April 2021
